TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GLEOLAN

AMINOLEVULINIC ACID HYDROCHLORIDE
Oncology Approved 2017-06-06
1
Indication
--
Phase 3 Trials
1
Priority Reviews
8
Years on Market

Details

Status
Prescription
First Approved
2017-06-06
Routes
ORAL
Dosage Forms
FOR SOLUTION

Companies

GLEOLAN Approval History

Loading approval history...

What GLEOLAN Treats

1 indications

GLEOLAN is approved for 1 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Glioma
Source: FDA Label

Drugs Similar to GLEOLAN

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

๐Ÿ”ฌ

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
โญ

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
๐Ÿ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GLEOLAN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. Gleolan is an optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery.

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.